Entity

Time filter

Source Type

Karnāl, India

Kalra S.,Bharti Hospital and BRIDE | Balhara Y.P.S.,All India Institute of Medical Sciences
Recent Patents on Endocrine, Metabolic and Immune Drug Discovery | Year: 2014

Thyroid dysfunction and psychiatric disorders share a bidirectional relation. Thyroid hormones have been found to affect the central nervous system both structurally and functionally. Conventional antidepressant drug therapy is characterized by a delayed and at times suboptimal response. Various strategies have been devised in order to circumvent this limitation. L- Thyroxine has been used as both acceleration therapy and augmentation therapy as adjuvant therapy with antidepressants. The hormone has also been used as monotherapy, both in prevention and management of depression. The potential use of thyroid hormone as an adjunct therapy in management of euthyroid depression and relevant patents has been discussed. © 2014 Bentham Science Publishers. Source


Kalra S.,Bharti Hospital and BRIDE
Journal of the Pakistan Medical Association | Year: 2014

Premixed biphasic insulin is the most commonly prescribed insulin in Pakistan, as well as in neighbouring countries. This article describes the rationale of using premixed insulin both for initiation and intensification, the evidence in its favour, and the guidelines supporting its use. The review discusses recent advances in the field of premixed insulin, especially insulin degludec aspart combination. Source


Kalra S.,Bharti Hospital and BRIDE
Journal of the Pakistan Medical Association | Year: 2013

The grand dame of diabetes pharmacotherapy, nearly a century old, insulin continues to be the subject of discovery and innovation. Fresh research, combined with extensive clinical experience, has brought newer facets of insulin use to the fore. Thus, insulin still exudes maiden charm. This review covers recent advances in the clinical pharmacology of insulin. Source


Kalra S.,Bharti Hospital and BRIDE | Gupta Y.,Government Medical College and Hospital
Diabetes Therapy | Year: 2015

Coformulations are a novel pharmaceutical development in diabetology. They are composed of two medicinal products, both of which maintain their distinct pharmacokinetic and pharmacodynamic properties. Currently available coformulations include combinations of basal and rapid-acting insulin, and basal and glucagon-like peptide 1 receptor agonists (GLP1RA). This review describes three coformulations which are in advanced stages of development, or are approved in certain markets. We discuss the basic and clinical pharmacology of these drugs, while describing clinical usage of the commercially available insulin degludec aspart (IDegAsp). © 2015, The Author(s). Source


Kalra S.,Bharti Hospital and BRIDE | Gupta Y.,Government Medical College
Recent Patents on Endocrine, Metabolic and Immune Drug Discovery | Year: 2014

Insulin analogues are a major improvement in diabetes pharmacotherapy. Rapid acting insulins have certain advantages over regular insulin, but there is a need to develop even faster acting insulin preparations, which mimic physiological insulin release in a better manner. This review discusses recent developments and patents in the field of Ultra-fast acting insulins. It classifies various approaches towards creation of an Ultra-fast acting insulin profile based upon the method used to achieve a faster onset of action. These include change in formulation of insulin, addition of excipients to insulin, and utilization of novel insulin sites or delivery methods. It examines the current state of evidence, and the developments in the field of newer insulin analogues & delivery methods. © 2014 Bentham Science Publishers. Source

Discover hidden collaborations